When did Insmed report Q3 2025 earnings?

Insmed (INSM) reported Q3 2025 earnings on October 30, 2025 before market open.

What were Insmed's Q3 2025 revenue and EPS?

Insmed reported revenue of $142.3M and diluted EPS of $-1.75 for Q3 2025.

Did Insmed beat estimates in Q3 2025?

Revenue beat the consensus estimate of $115.4M by $26.9M. EPS missed the consensus estimate of $-1.33 by $0.42.

How did Insmed's Q3 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 52.4% from $93.4M a year earlier and diluted EPS declined 37.8% from $-1.27.

Where can I find Insmed's Q3 2025 SEC filings?

You can read the 10-Q periodic report (0001104506-25-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.

Insmed INSM Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$142.3MBeat by $26.9M Diluted EPS-$1.75Miss by $0.42

Revenue estimate$115.4M

EPS estimate-$1.33

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$390.1M

EPS estimate-$0.75

Financials

Q3 2025

Income statement

See full

Revenue$142.3M+52.4%

Gross profit$113.0M+56.4%

Operating income-$366.0M-71.5%

Net income-$370.0M-67.8%

EPS (diluted)-$1.75-37.8%

Balance sheet

See full

Cash & equivalents$334.8M-27.5%

Total debt$576.3M-42.4%

Total equity$945.6M+95.6%

Total assets$2.4B+15.0%

Cash flow

See full

Operating cash flow-$219.8M-21.5%

CapEx$2.4M-34.5%

Free cash flow-$222.2M-20.4%

Valuation & ratios

Valuation

as of 09/30/25

See full

Market cap$30.44B+170%

Enterprise value$30.68B+159%

P/S68.1×+35.2×

Profitability

See full

Gross margin76.5%-0.7pp

Operating margin-258.9%+21.0pp

Net margin-264.8%+14.2pp

FCF margin-202.7%+20.8pp

Returns & leverage

See full

Return on equity-165.7%—

Debt / equity0.6×-1.5×

Current ratio4.6×-1.7×

Segments

By product

See full

ARIKAYCE external R&D expenses$114.3M+22.3%

Versus estimates

Revenue

Q1 2026$306.0MBeat by $5.2M Q4 2025$263.8MBeat by $32.6M

Q3 2025$142.3MBeat by $26.9M

Q2 2025$107.4MBeat by $3.3M Q1 2025$92.8MBeat by $1.4M Q4 2024$104.4MBeat by $2.4M

Diluted EPS

Q1 2026-$0.76Beat by $0.14 Q4 2025-$1.54Miss by $0.47

Q3 2025-$1.75Miss by $0.42

Q2 2025-$1.70Miss by $0.40 Q1 2025-$1.42Miss by $0.08 Q4 2024-$1.32Miss by $0.15

Ask the moment Insmed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Insmed report Q3 2025 earnings?: Insmed (INSM) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Insmed's Q3 2025 revenue and EPS?: Insmed reported revenue of $142.3M and diluted EPS of $-1.75 for Q3 2025.
Did Insmed beat estimates in Q3 2025?: Revenue beat the consensus estimate of $115.4M by $26.9M. EPS missed the consensus estimate of $-1.33 by $0.42.
How did Insmed's Q3 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 52.4% from $93.4M a year earlier and diluted EPS declined 37.8% from $-1.27.
Where can I find Insmed's Q3 2025 SEC filings?: You can read the 10-Q periodic report (0001104506-25-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.